Results 171 to 180 of about 2,867,692 (324)
Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation [PDF]
Wendy A. Brown+4 more
openalex +1 more source
In the study, UBE2C was found to be significantly overexpressed in breast cancer and transcriptionally regulated by FOXM1. Inhibition of UBE2C suppressed proliferation, induced senescence, and sensitized breast cancer cells to doxorubicin. Mechanistically, UBE2C inhibition promoted Parkin‐mediated K63‐linked ubiquitination of TOP2A.
Yihui Yang+12 more
wiley +1 more source
The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase‐2, in humans [PDF]
C J Hawkey+5 more
openalex +1 more source
scRNA sequencing reveals distinct tumor ecosystem features in CAYA‐PTC, marked by enriched CD4T_Tfh, CD8T_Tex cells, and rapid malignant thyrocyte differentiation (absent of mild‐state BRAF‐like population) toward invasive states. Prominent emCAF_LAMP5 populations interact with endothelial cells and thyrocytes facilitate angiogenesis and metastasis ...
Kai Guo+15 more
wiley +1 more source
Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors [PDF]
Julie A. Stading+2 more
openalex +1 more source
This study identifies MTCH2 as a crucial regulator of ferroptosis in colorectal cancer (CRC) progression. High expression of MTCH2 is correlated with poor prognosis in CRC patients. Furthermore, MTCH2 depletion induces ferroptosis to suppress CRC liver metastasis via the E2F4/TFRC axis and sensitizes tumors to sorafenib treatment, supporting MTCH2 as a
Pu Xing+18 more
wiley +1 more source
Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation [PDF]
Alexzander Asea+7 more
openalex +1 more source
Irisin is a crucial plasma biomarker and promising therapeutic target that reflects disease severity, pulmonary vascular remodeling status and clinical outcome in patients with pulmonary arterial hypertension (PAH). As a novel protective factor, irisin is downregulated in PAH. By ubiquitination, irisin promotes Enolase 1 degradation and suppresses cell
Na Sun+15 more
wiley +1 more source